Justice Jackson Pens Unanimous Decision Backed by SCOTUS Conservatives
Summary
The Supreme Court made a unanimous decision in a patent dispute between Hikma Pharmaceuticals and Amarin Pharma. Justice Ketanji Brown Jackson wrote the opinion, which reversed a lower court ruling about when generic drug makers can be sued for patent infringement if they use "skinny labels" to exclude patented uses.Key Facts
- The Supreme Court ruled 9-0 in favor of Hikma Pharmaceuticals.
- Justice Ketanji Brown Jackson authored the unanimous opinion.
- The case involved whether generic drug companies can be held liable for patent infringement when they use "skinny labels."
- "Skinny labels" mean the generic drugs exclude patented uses on their labels to avoid infringement.
- Amarin Pharma sued Hikma after Hikma tried to sell a generic Vascepa with a skinny label.
- The lower district court dismissed the case, but an appeals court allowed it to continue before the Supreme Court reversed that decision.
- The ruling clarifies legal rules for patent claims related to generic drugs under the Hatch-Waxman Act.
- The case will now return to lower courts for further review using the Supreme Court’s guidance.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.